Arboretum LifeSciences launched Tuesday with $30 million in series A funds to build an AI-genomics platform aimed at drug discovery in common diseases, using genetic testing plus longitudinal clinical data to identify patient subgroups most likely to benefit from targeted therapies. For oncology-minded clinicians, the pitch is clear: apply the molecular-segmentation playbook that transformed cancer care to larger populations in coronary artery disease, diabetes, and neurodegeneration.

Why It Matters To Oncology

• Arboretum is borrowing directly from oncology's precision-medicine model: use molecular information to define biologically distinct patient groups, then develop and test therapies in the patients most likely to respond.

• That could sharpen target selection, enrich clinical trials, and reduce the noise that often sinks programs in heterogeneous common diseases.

• For cancer drug hunters, it's a familiar thesis in a new setting — biomarker-driven development expanded beyond oncology and rare disease.

The Financials

• The company launched with $30 million in hand through a series A.

• Investors include Amgen, F-Prime, GV, .406 Ventures, and Hims & Hers.

• CEO Anthony Philippakis is also a general partner at GV; the founding team includes leaders from the Broad Institute's Data Sciences Platform.

What They're Saying

• Amgen's Michael Montalto said developers in common diseases have lacked access to the large-scale genomic and clinical datasets needed to translate genetic insights into new treatments.

• Philippakis framed the strategy as a replay of oncology's bet from 20 years ago: treat smaller, molecularly defined populations for more transformative outcomes.

• President Clare Bernard said trial design should follow each patient's biological signal rather than population averages, with the goal of improving both therapeutic options and evidence generation.

What's Next

• Arboretum plans to work with health systems to expand clinically indicated genetic testing and link results to longitudinal records, creating large, fully genotyped cohorts.

• Patients would receive actionable genomic findings as part of care and, if they consent, could be recontacted for future research and trials.

• Initial partnerships include Advocate Health, Geisinger, Providence Healthcare, and Cardiovascular Associates of America, spanning teleconsult-supported cardiovascular testing, biobank integration, registry-linked trial support, and point-of-care genetic testing.